Polybromo-1 (PBRM1), a SWI/SNF complex subunit is a prognostic marker in clear cell renal cell carcinoma

BJU International

Volumn 113, Issue 5 B, 2014, Pages

  Da Costa, Walter H ^a   Rezende, Mariana ^a   Carneiro, Felipe C ^a   Rocha, Rafael M ^a   Da Cunha, Isabela W ^a   Carraro, Dirce M ^a   Guimaraes, Gustavo C ^a   De Cassio Zequi, Stenio ^a  

^a A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

Kidney; Molecular marker; PBRM1; Prognosis; Renal cell carcinoma

Indexed keywords

MESSENGER RNA; POLYBROMO 1 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; MOLECULAR MARKER; NUCLEAR PROTEIN; PBRM1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY SURGERY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR INVASION; TUMOR RECURRENCE; TUMOR VOLUME; BIOSYNTHESIS; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PBRM1; PROGNOSIS; VERY ELDERLY;

KIDNEY; MOLECULAR MARKER; PBRM1; PROGNOSIS; RENAL CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS;

EID: 84902342985     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12426     Document Type: Article

References (23)

1. Ljungberg B, Campbell SC, Choi HY et al. The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615-21
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
3. Rosner I, Bratslavsky G, Pinto PA, Linehan WM. The clinical implications of the genetics of renal cell carcinoma. Urol Oncol 2009; 27: 131-6
4. Mandriota SJ, Turner KJ, Davies DR et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002; 1: 459-68 (Pubitemid 41039126)
5. Dalgliesh GL, Furge K, Greenman C et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-3
6. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-42
7. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-92
8. Sekine I, Sato M, Sunaga N et al. The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer. Oncogene 2005; 24: 2735-8 (Pubitemid 40593101)
9. Volpe A, Patard JJ. Prognostic factors in renal cell carcinoma.World J Urol 2010; 28: 319-27
10. Klatte T, Seligson DB, LaRochelle J et al. Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev 2009; 18: 894-900
11. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 2010; 10: 457-69
12. Xia W, Nagase S, Montia AG et al. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer. Cancer Res 2008; 68: 1667-74 (Pubitemid 351416550)
13. Burrows AE, Smogorzewska A, Elledge SJ. Polybromo-associated BRG1-associated factor components BRD7 and BAF180 are critical regulators of p53 required for induction of replicative senescence. Proc Natl Acad Sci USA 2010; 107: 14280-5
14. Shain AH, Pollack JR. The spectrum of SWI/SNF mutations, ubiquitous in human cancers. PLoS ONE 2013; 8: e55119
15. Pawłowski R, Muhl SM, Sulser T, Krek W, Moch H, Schraml P. Loss of PBRM1 expression is associated with renal cell carcinoma progression. Int J Cancer 2012; 132: 11-7
16. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med 2012; 366: 883-92
17. Hakimi AA, Chen YB, Wren J et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013; 63: 848-54
18. Kapur P, Pena-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14: 159-67
19. Hakimi AA, Ostrovnaya I, Reva BA et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a Report by MSKCC and the KIRC TCGA Research Network. Clin Cancer Res 2013; 19: 3259-67
20. Brannon AR, Reddy A, Seiler M et al. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010; 1: 152-63
21. Drev P, Grazio SF, Bracko M. Tissue microarrays for routine diagnostic assessment of HER2 status in breast carcinoma. Appl Immunohistochem Mol Morphol 2008; 16: 179-84
22. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008; 26: 5630-7
23. Torhorst J, Bucher C, Kononen J et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints.Am J Pathol 2001; 159: 2249-56 (Pubitemid 33104278)